RNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Avidity Biosciences's Enterprise Value is $2,446.89 Mil. Avidity Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-188.51 Mil. Therefore, Avidity Biosciences's EV-to-FCF for today is -12.98.
The historical rank and industry rank for Avidity Biosciences's EV-to-FCF or its related term are showing as below:
During the past 6 years, the highest EV-to-FCF of Avidity Biosciences was 5.73. The lowest was -328.72. And the median was -5.65.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2024-12-15), Avidity Biosciences's stock price is $32.49. Avidity Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.890. Therefore, Avidity Biosciences's PE Ratio (TTM) for today is At Loss.
The historical data trend for Avidity Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avidity Biosciences Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EV-to-FCF | Get a 7-Day Free Trial | - | -16.53 | -7.52 | -6.82 | -1.07 |
Avidity Biosciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-FCF | Get a 7-Day Free Trial | 0.33 | -1.07 | -10.66 | -19.97 | -20.58 |
For the Biotechnology subindustry, Avidity Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Avidity Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Avidity Biosciences's EV-to-FCF falls into.
Avidity Biosciences's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 2446.891 | / | -188.511 | |
= | -12.98 |
Avidity Biosciences's current Enterprise Value is $2,446.89 Mil.
Avidity Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-188.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avidity Biosciences (NAS:RNA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Avidity Biosciences's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 32.49 | / | -2.890 | |
= | At Loss |
Avidity Biosciences's share price for today is $32.49.
Avidity Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.890.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Avidity Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Arthur A Levin | officer: Chief Scientific Officer | 1896 RUTHERFORD ROAD, CARLSBAD CA 92008 |
Teresa Mccarthy | officer: Chief Human Resources Officer | 10975 N TORREY PINES RD #150, LA JOLLA CA 92037 |
Michael F Maclean | officer: Chief Financial Officer | 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
Tamar Thompson | director | C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037 |
W. Michael Flanagan | officer: Chief Technical Officer | C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037 |
Sarah Boyce | director, officer: President and CEO | C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010 |
Eric Mosbrooker | director | C/O HORIZON PHARMA, PLC, ADELAIDE CHAMBERS, PETER STREET, DUBLIN 8 L2 000000 |
Rtw Investments, Lp | 10 percent owner | 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
Jean Jinsun Kim | director | C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037 |
Jae B. Kim | officer: Chief Medical Officer | C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037 |
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Kaye Edward M. Md | director | 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011 |
Cormorant Global Healthcare Master Fund, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Bihua Chen | director, 10 percent owner | C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Roderick Wong | director, 10 percent owner | C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
From GuruFocus
By PRNewswire • 10-03-2024
By PRNewswire • 06-17-2024
By GuruFocus News • 11-08-2024
By PRNewswire • 08-09-2024
By PRNewswire • 08-05-2024
By PRNewswire • 08-19-2024
By GuruFocus News • 11-15-2024
By GuruFocus News • 11-14-2024
By PRNewswire • 06-12-2024
By PRNewswire • 06-21-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.